Therapeutische gebieden

Gaucher disease in children

Beyfortus®▼(nirsevimab): effectiveness and public health impact in the real world

  Beyfortus

DUPIREAL: Two-Year Turning Point with Dupilumab in CRSwNP

The results from the DUPIREAL real-world study reinforce the efficacy of dupilumab demonstrated in the SINUS-24 and SINUS-52 randomized clinical trials and are consistent with the approved SmPC.^1,2,3,4 DUPIREAL is the largest long-term real-world study (n=926) evaluating the effectiveness of dupilumab, including treatment response, disease control and remission, in severe uncontrolled CRSwNP over 2 years.^2,3

Accelerate the identification of rare diseases

accelRare^® is a pre-diagnosis and differential diagnosis tool. Developed, tested and validated in collaboration with 67 European rare disease specialists across multiple disciplines.

Vaccin gerelateerde materialen bestellen

Atopic Dermatitis Control Tool (ADCT)

Webinar: Disease Modification in Atopic Dermatitis

Breath Breaks: ERS Lunchsessies 2025

EADV 2025 with Sanofi: Advanced Dermatology Resources

Discover Sanofi at EADV2025 featuring BioDay registry findings, expert panels, and networking opportunities for dermatology professionals in Paris.

Hybride Zorg: eDerm Lunch & Learn

AI & WIJ: Kunstmatige intelligentie in de medische praktijk

Geaccrediteerde nascholingen in de dermatologie

Hier vindt u een overzicht van onze geaccrediteerde nascholingen voor zorgprofessionals in de dermatologie. De nascholingen zijn praktijkgericht, actueel en ontwikkeld in samenwerking met experts uit het veld. U kunt kiezen voor interactieve workshops, Lunch & Learn-sessies of on-demand e-learnings.